Stem Cell Clinic

Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference

By Global News Feed

BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will participate in a panel discussion at TD Cowen’s 44th Annual Health Care Conference in Boston, MA, on Tuesday, March 5, 2024, at 12:50 p.m. ET.

Continue reading here:
Enliven Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference

ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

By Global News Feed

PORTLAND, Maine, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter and year ended December 31, 2023.

Read the original post:
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2023

Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

By Global News Feed

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44th Annual Cowen Health Care Conference, taking place March 4-6, 2024, in Boston, Massachusetts.

Read the original:
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

By Global News Feed

FOSTER CITY, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in the following upcoming investor conferences in March.

Here is the original post:
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

By Global News Feed

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2023.

Read the original post:
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2023 Financial Results

Supernus Announces Fourth Quarter and Full Year 2023 Financial Results

By Global News Feed

___________________________________________(1) Total revenues excluding Trokendi XR net product sales is a non-GAAP measure and is calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP). A reconciliation of this measure to Total revenues (GAAP) is included under the heading "Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding Trokendi XR net product sales."(2) Operating earnings (non-GAAP) is a non-GAAP measure and is calculated as Operating earnings (loss) (GAAP) plus amortization of intangible assets, share-based compensation, contingent consideration expense (gain), intangible asset impairment charges, and depreciation. A reconciliation of this measure to Operating earnings (loss) (GAAP) is included under the heading "Reconciliation of GAAP Operating earnings (loss) to Non-GAAP Operating earnings."(3) A reconciliation of the operating earnings (non-GAAP) guidance is included under the heading "Full Year 2024 Financial Guidance - GAAP to Non-GAAP Adjustments."

View original post here:
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

By Global News Feed

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that company management will participate in TD Cowen’s 44th Annual Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Details of participation are as follows:

Continue reading here:
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET

By Global News Feed

HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.

Read more:
Harvard Bioscience Schedules Fourth Quarter 2023 Earnings Conference Call for March 7, 2024 at 8:00 AM ET

→←